Atossa Genetics Inc Stock Nasdaq
Equities
US04962H1005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Jul. 02 | Atossa Therapeutics Names Heather Rees CFO | MT |
Jul. 02 | Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 165M |
---|---|---|---|---|---|
Net income 2024 * | -30M | Net income 2025 * | -35M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.46
x | P/E ratio 2025 * |
-4.76
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Atossa Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Heather Rees
DFI | Director of Finance/CFO | 51 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |